GITR activation ex vivo impairs CD8 T cell function in people with HIV on antiretroviral therapy

Gubser, Céline; Pascoe, Rachel D.; Chang, Judy; Chiu, Chris; Solomon, Ajantha; Cao, Rosalyn; Rasmussen, Thomas A.; Lewin, Sharon R.

doi:10.1016/j.isci.2023.108165

Cited by 3 publications

(1 citation statement)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The GC-induced TNF receptor family-related protein (GITR) is an immune checkpoint molecule involved in the regulation of T cell responses [ 220 ]. The phenomenon that the single structural domain of GITR mediates its binding with ligands suggests that this unique mode of action may represent an ancient binding pattern in the evolution of the TNF/TNFR superfamily [ 221 , 222 ]. In contrast, other TNFR superfamily members have evolved to bind with ligands through two distinct structural domains for specificity and high affinity [ 223 ].…”

Section: Research On Reshaping the Tmementioning

confidence: 99%

Glucocorticoids in lung cancer: Navigating the balance between immunosuppression and therapeutic efficacy

Xu,

Ye,

Cao

et al. 2024

Heliyon

View full text Add to dashboard Cite

Section: Research On Reshaping the Tmementioning

confidence: 99%

Glucocorticoids in lung cancer: Navigating the balance between immunosuppression and therapeutic efficacy

Xu,

Ye,

Cao

et al. 2024

Heliyon

View full text Add to dashboard Cite

Protocol for measuring killing capacity and intracellular cytokine production of human HIV antigen-specific CD8 T cells using flow cytometry

Gubser,

Pascoe,

Trautmann

et al. 2024

STAR Protocols

View full text Add to dashboard Cite

Immune checkpoint inhibitors in infectious disease

King,

Lewin

2024

Immunological Reviews

View full text Add to dashboard Cite

SummaryFollowing success in cancer immunotherapy, immune checkpoint blockade is emerging as an exciting potential treatment for some infectious diseases, specifically two chronic viral infections, HIV and hepatitis B. Here, we will discuss the function of immune checkpoints, their role in infectious disease pathology, and the ability of immune checkpoint blockade to reinvigorate the immune response. We focus on blockade of programmed cell death 1 (PD‐1) to induce durable immune‐mediated control of HIV, given that anti‐PD‐1 can restore function to exhausted HIV‐specific T cells and also reverse HIV latency, a long‐lived form of viral infection. We highlight several key studies and future directions of research in relation to anti‐PD‐1 and HIV persistence from our group, including the impact of immune checkpoint blockade on the establishment (AIDS, 2018, 32, 1491), maintenance (PLoS Pathog, 2016, 12, e1005761; J Infect Dis, 2017, 215, 911; Cell Rep Med, 2022, 3, 100766) and reversal of HIV latency (Nat Commun, 2019, 10, 814; J Immunol, 2020, 204, 1242), enhancement of HIV‐specific T cell function (J Immunol, 2022, 208, 54; iScience, 2023, 26, 108165), and investigating the effects of anti‐PD‐1 and anti‐CTLA‐4 in vivo in people with HIV on ART with cancer (Sci Transl Med, 2022, 14, eabl3836; AIDS, 2021, 35, 1631; Clin Infect Dis, 2021, 73, e1973). Our future work will focus on the impact of anti‐PD‐1 in vivo in people with HIV on ART without cancer and potential combinations of anti‐PD‐1 with other interventions, including therapeutic vaccines or antibodies and less toxic immune checkpoint blockers.

show abstract

GITR activation ex vivo impairs CD8 T cell function in people with HIV on antiretroviral therapy

Cited by 3 publications

References 49 publications

Glucocorticoids in lung cancer: Navigating the balance between immunosuppression and therapeutic efficacy

Glucocorticoids in lung cancer: Navigating the balance between immunosuppression and therapeutic efficacy

Protocol for measuring killing capacity and intracellular cytokine production of human HIV antigen-specific CD8 T cells using flow cytometry

Immune checkpoint inhibitors in infectious disease

Contact Info

Product

Resources

About